Assessing the Dual Activity of a Chalcone–Phthalocyanine Conjugate: Design, Synthesis, and Antivascular and Photodynamic Properties

Photodynamic therapy (PDT) and vascular-disrupting agents (VDA) each have their advantages in the treatment of solid tumors, but also present drawbacks. In PDT, hypoxia at the center of the tumor limits conversion of molecular oxygen into singlet oxygen, while VDAs are deficient at affecting the rim...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2013-10, Vol.10 (10), p.3706-3716
Main Authors: Tuncel, Sinem, Trivella, Aurélien, Atilla, Devrim, Bennis, Khalil, Savoie, Huguette, Albrieux, Florian, Delort, Laetitia, Billard, Hermine, Dubois, Virginie, Ahsen, Vefa, Caldefie-Chézet, Florence, Richard, Claire, Boyle, Ross W, Ducki, Sylvie, Dumoulin, Fabienne
Format: Article
Language:English
Subjects:
Cell Line
Cell Movement - drug effects
Chalcone - chemistry
Chalcone - pharmacology
Humans
Indoles - chemistry
Indoles - pharmacology
Life Sciences
Molecular Structure
Photochemotherapy - methods
Photosensitizing Agents - chemical synthesis
Photosensitizing Agents - chemistry
Photosensitizing Agents - pharmacology
Singlet Oxygen - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Photodynamic therapy (PDT) and vascular-disrupting agents (VDA) each have their advantages in the treatment of solid tumors, but also present drawbacks. In PDT, hypoxia at the center of the tumor limits conversion of molecular oxygen into singlet oxygen, while VDAs are deficient at affecting the rim of the tumor. A phthalocyanine–chalcone conjugate combining the VDA properties of chalcones with the PDT properties of phthalocyanines was designed to address these deficiencies. Its vascular targeting, photophysical, photochemical, photodynamic activities are reported herein.
ISSN:1543-8384
1543-8392
DOI:10.1021/mp400207v